DekaBank Deutsche Girozentrale grew its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 392.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,746 shares of the company’s stock after acquiring an additional 11,754 shares during the quarter. DekaBank Deutsche Girozentrale owned 0.06% of USANA Health Sciences worth $1,955,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Royce & Associates LP raised its position in USANA Health Sciences by 66.4% in the 1st quarter. Royce & Associates LP now owns 381 shares of the company’s stock valued at $32,000 after buying an additional 152 shares during the last quarter. NumerixS Investment Technologies Inc bought a new position in USANA Health Sciences in the 4th quarter valued at $34,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in USANA Health Sciences by 23.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 858 shares of the company’s stock valued at $101,000 after purchasing an additional 165 shares during the period. Great West Life Assurance Co. Can grew its stake in USANA Health Sciences by 43.8% in the 4th quarter. Great West Life Assurance Co. Can now owns 1,516 shares of the company’s stock valued at $172,000 after purchasing an additional 462 shares during the period. Finally, SG Americas Securities LLC bought a new position in USANA Health Sciences in the 1st quarter valued at $193,000. Institutional investors own 59.70% of the company’s stock.
USANA Health Sciences stock traded up $2.75 during trading hours on Friday, reaching $79.43. The company had a trading volume of 2,963,941 shares, compared to its average volume of 277,941. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of 15.39 and a beta of 0.45. USANA Health Sciences, Inc. has a 12-month low of $69.58 and a 12-month high of $137.95. The stock has a 50-day simple moving average of $75.12.
USNA has been the subject of several analyst reports. Tigress Financial initiated coverage on USANA Health Sciences in a research note on Tuesday, April 16th. They issued a “buy” rating for the company. Pivotal Research restated a “buy” rating and issued a $105.00 target price on shares of USANA Health Sciences in a research note on Wednesday, May 1st. Finally, ValuEngine cut USANA Health Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, May 22nd.
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Featured Story: What are the risks of holding treasury bonds?
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.